3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
120
Lymphoma
90
Lymphoma, Large B-Cell, Diffuse
79
Precursor Cell Lymphoblastic Leukemia-Lymphoma
34
Burkitt Lymphoma
31
Multiple Myeloma
26
Lymphoma, Non-Hodgkin
26
Lymphoma, Follicular
26
Leukemia
26
Hodgkin Disease
24
Lymphoma, Mantle-Cell
18
Neoplasms
16
Lymphoma, T-Cell, Peripheral
16
Lymphoma, B-Cell
14
Lymphoma, Large-Cell, Immunoblastic
12
Lymphoma, Large-Cell, Anaplastic
11
Dendritic Cell Sarcoma, Interdigitating
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Recurrence
8
Lymphoma, B-Cell, Marginal Zone
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Neoplasms, Plasma Cell
7
Neoplasm Metastasis
7
Waldenstrom Macroglobulinemia
6
Primary Myelofibrosis
6
Lymphoma, T-Cell
6
Immunoblastic Lymphadenopathy
6
HIV Infections
5
Graft vs Host Disease
5
Blast Crisis
5
Interventions
enzalutamide
3
Abiraterone Acetate
2
testosterone enanthate
1
pembrolizumab
1
disitamab vedotin
1
abiraterone
1
Radium-223
1
Prednisone
1
Ketoconazole
1
Hydrocortisone
1
Flutamide
1
Calcitriol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Castration-resistant Prostate Cancer
×
Prednisone
×
Clear all
NCT02429193
2020-01-13
BARRIER-P
University Health Network, Toronto
Phase 2
Completed
16 enrolled